Cell line | Target | IC50 (nM) |
---|---|---|
Induction of apoptosis | ||
HMC1.1 | KIT V560G | 31 |
HMC1.2 | KIT V560G/D816V | not reached* |
p815 | KIT D814Y (murine) | 341 |
Kasumi-1 | KIT N822K | 67 |
M-07e + SCF | KIT-activated | 78 |
M-07e + GM-CSF | unspecific stimulation | not reached* |
EOL-1 | FIP1L1-PDGFRA | < 1 |
K562 | BCR/ABL | not reached* |
HL60 | N/A | not reached* |
Jurkat | N/A | not reached* |
MV4;11 | FLT3 ITD (hemizygous) | 2 |
MOLM14 | FLT3 ITD | 3 |
GIST822 | KIT K642E | 109 |
GIST48 | KIT V560D/D820A | not reached* |
Pat.368 | FLT3 amplification ? | 2998 |
Pat.601 | FLT3 ITD | 876 |
Pat.695, 20% FBS | FLT3 ITD | 2335 |
Pat.695, 0.5% FBS | FLT3 ITD | 25 |
Pat.139, 20% FBS | FLT3 ITD, Relaps | 760 |
Pat.139, 0.5% FBS | FLT3 ITD, Relaps | 10 |
Reduction of viable cells | ||
Pat.507 | CBF AML (KIT WT) | 1275 |
Pat.317 | CBF AML (KIT D816Y) | 1294 |
Pat.521 | CBF AML (KIT WT) | 2018 |
Pat.305 | CBF AML (KIT WT) | 2954 |
Pat.511 | CBF AML (KIT WT) | 4272 |
Pat.281 | CBF AML (KIT WT) | 5758 |
Pat.279 | CBF AML (KIT WT) / FLT3 amplification? (subclone) | 6607 |
Pat.523 | CBF AML (KIT WT) | 7175 |
Pat.361 | CBF AML (KIT D816V) | 8443 |
Pat.239 | CBF AML (KIT D816V) | not reached* |